Clinical trials: Hepatic Complication
BRAF Gene Mutation, Hepatic Complication
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction.
- Conditions
- BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
- Trial name
- NCT01907802
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 18 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
End-stage Liver Disease, Renal Insufficiency
Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation
The objective of this study is to compare the effects of two liver transplant immunosuppression regimens on renal function. Patients receiving the standard combination of prednisone and high-dose tacrolimus, a drug with known…
- Conditions
- End-stage Liver Disease, Renal Insufficiency, Renal Failure
- Trial name
- NCT00656266
- Testing
- mycophenolate mofetil
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine
Liver Failure, Renal Failure
Assessment of Renal Function in Cirrhotic Patients
The purpose of this study is to help determine whether cystatin C is a more sensitive laboratory measurement for renal function in cirrhotic patients.
- Trial name
- NCT01895114
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Baylor Research Institute
Post-Hepatectomy Liver Failure, Liver Failure
CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure
Removing a large part of the liver (major hepatectomy) can cure primary and secondary liver cancers, but it carries the risk of post-hepatectomy liver failure (PHLF), a serious complication in which the liver left behind - the…
- Conditions
- Post-Hepatectomy Liver Failure, Liver Failure, Liver Neoplasms, Carcinoma, Hepatocellular
- Trial name
- BEYOND-SIZE (NCT07727759)
- Testing
- Preoperative CT volumetry with hepatic vascular deformation mapping (VDM)
- Where
- 3 sites in Egypt
- Volunteers
- 1,070 people
- Sponsor
- Minia University
Seriously Ill Patients, Cancer
Goals of Care Conversations Study
The long term goal is to improve quality of care in Veterans with serious illnesses by aligning medical care with Veterans' goals and values.
- Conditions
- Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease
- Trial name
- LSTDI (NCT05001009)
- Testing
- Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement
- Where
- 3 sites in United States
- Volunteers
- 2,859 people
- Sponsor
- VA Office of Research and Development
Hepatic Impairment, Renal Impairment
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.
- Trial name
- NCT05112419
- Testing
- Zibotentan
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pharmacokinetics of MDV3100, Healthy Subjects
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
This study will assess the influence of hepatic impairment on the pharmacokinetics, safety and tolerability of a single dose of MDV3100 in male subjects. The study will consist of two treatment arms.
- Conditions
- Pharmacokinetics of MDV3100, Healthy Subjects, Kidney Diseases
- Trial name
- NCT01901133
- Testing
- MDV3100
- Where
- Moldova
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Hepato-Renal Syndrome, Portal Hypertension
MRI to Assess the Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome (HRS-AKI)
Heptorenal syndrome (HRS) is divided into two types. A non-acute kidney injury (NAKI-HRS), which is predominantly related to end-stage disease and a more acute kidney injury (HRS-AKI).
- Conditions
- Hepato-Renal Syndrome, Portal Hypertension, Acute Kidney Injury, Liver Diseases
- Trial name
- NCT03483272
- Where
- 2 sites in Denmark
- Volunteers
- 11 people
- Sponsor
- Hvidovre University Hospital
Liver Diseases, Liver Cirrhosis
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial.
- Conditions
- Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
- Trial name
- CHANCE (NCT04613921)
- Testing
- Observational Protocol
- Where
- 106 sites in United States, Argentina and 25 more
- Volunteers
- 3,000 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Liver Injury
Liver Ischemia-reperfusion Injury and Clinical Data Analysis
Searching for new targets for the diagnosis and treatment of liver ischemia-reperfusion injury.
- Trial name
- NCT06080308
- Testing
- No intervention
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Qin Zhang
Hepatic Ischemia-reperfusion Injury
Hypothermic Perfusion During Hemihepatectomy
Rationale Currently, hepatic resection is often the only curative treatment for primary or secondary hepatic malignancies and is also frequently performed in patients with benign liver tumors to prevent malignant transformation…
- Trial name
- NCT01499979
- Testing
- In situ hypothermic perfusion
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chronic Kidney Diseases, Diabetes
Precision Medicine Approach to Unravel the Risk Factors for Renal, Cardiovascular, Ophthalmologic, Neurologic and Hepatic Complications of Metabolic Disorders
There is currently no way to predict the progression of chronic kidney disease in patients with metabolic disease(s). Furthermore, the mechanisms responsible for the development and/or progression of complications remain largely…
- Conditions
- Chronic Kidney Diseases, Diabetes, Obesity
- Trial name
- PRECIMETAB (NCT05307172)
- Where
- France
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
End Stage Liver DIsease, Complication
Real World Study of End-stage Liver Disease in China
The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of complications.
- Trial name
- NCT04037995
- Testing
- No intervation
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Huashan Hospital
Chronic Kidney Diseases, NAFLD
Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with…
- Trial name
- NAFLD (NCT04779905)
- Testing
- urinary albumbin/creatinine ratio
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Sohag University
Hepatorenal Syndrome, Cirrhosis, Liver
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF…
- Conditions
- Hepatorenal Syndrome, Cirrhosis, Liver, Acute-On-Chronic Liver Failure, AKI
- Trial name
- NCT05434286
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 75 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cirrhosis
Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
The main objective of the study will determine if patients with liver cirrhosis, anticoagulation free survival improves hypertension decompensation portal and / or transplantation without serious side effects.
- Trial name
- CIRROXABAN (NCT02643212)
- Testing
- Rivaroxaban
- Where
- 14 sites in Spain
- Volunteers
- 160 people
- Sponsor
- David Garcia Cinca
Polycystic Ovary Syndrome
Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome
This is a prospective randomized, double-blind placebo-controlled trial of 6 months' duration evaluating the effect of fenofibrate (200 mg/day) in females with polycystic ovary syndrome and mild hypertriglyceridemia.
- Trial name
- NCT00884819
- Testing
- Fenofibrate
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Colorectal Adenocarcinoma, Hepatic Carcinoma
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of subgroups with similar molecular…
- Conditions
- Colorectal Adenocarcinoma, Hepatic Carcinoma, Kidney Adenocarcinoma
- Trial name
- ExhauCRF (NCT03149523)
- Where
- 3 sites in France
- Volunteers
- 150 people
- Sponsor
- European Georges Pompidou Hospital
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)